

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/563,278
Applicants: Jacques ABRAINI, et al.
Filed Internationally: July 23, 2004
US National: January 4, 2006
Title: INHALABLE GASEOUS MEDICINE BASED ON XENON AND
NITROUS OXIDE
TC/A.U.: Unknown
Examiner: Unknown
Docket No.: Serie 6132
Customer No.: 40582

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the non-US patent documents cited on the attached PTO Form 1449 is enclosed.

No fee is due at this time in accordance with 37 C.F.R. § 1.97. However, the Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 01-1375.

To assist the Examiner, the documents are listed on the attached form PTO-1449.
It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned. This paper is submitted in duplicate.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'B.S. Clark', is written over a horizontal line.

Brandon S. Clark, Reg. No. 59,020

Date: October 6, 2006

Air Liquide
Intellectual Property Department
2700 Post Oak Boulevard, Suite 1800
Houston, Texas 77056
(713) 624-8787 Phone – (713) 624-8950 Fax

INFORMATION DISCLOSURE CITATION (USE SEVERAL SHEETS IF NECESSARY)				ATTY. DOCKET NO. Serie 6132		SERIAL NO. 10/563,278	
				APPLICANT(S) Jacques ABRAINI, et al.			
				FILING DATE January 4, 2006		GROUP Unknown	

U.S. PATENT DOCUMENTS							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date	
A1	US 6 274 633	8/14/2001	Franks et al.				
A2	US 4 820 258 Equivalent of FR 2 596 989	4/11/1989	Mondain-Monval				

FOREIGN PATENT DOCUMENTS							
Document Number	Date	Country	Class	Subclass	Translation		
B1 FR 2 596 989 Equivalent: US 4 820 258	10/16/1987	France			Yes	No	
B2 WO 00 53192	9/14/2000	PCT					
B3 EP 0 861 672	9/02/1998	Europe					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
C1	International Search Report for PCT/FR2004/050352
C2	Lichtigfeld et al.: <i>Psychotropic analgesic nitrous oxide and neurotransmitter mechanisms involved in the alcohol withdrawal state</i> , Intern. J. Neuroscience, 1994, vol. 76, no. 1-2, pp. 17-33
C3	David et al.: <i>Reduction of ischemic brain damage by nitrous oxide and xenon</i> , J. Cerebral Blood Flow and Metabolism, vol. 23, no. 10, October 10, 2003, pp. 1168-1173
C4	Del Arco et al.: <i>Amphetamine increases the extracellular concentration of glutamate in striatum of the awake rat: involvement of high affinity transporter mechanisms</i> , Neuropharmacology, 1999, vol. 38, pp. 943-954
C5	David et al.: <i>Inhibition of the glutamate transporter by L-trans-PDC in the nucleus accumbens prevents the locomotor response to amphetamine</i> , Neuropharmacology, 2001, vol. p. 409-411
C6	Franks et al.: <i>How does xenon produce anaesthesia?</i> , Nature, 1998, vol. 396, p. 324
C7	Jevtovic-Todorovic et al.: <i>Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin</i> , Nature Med., 1998, vol. 4, pp. 460-463
C8	Lichtigfeld et al.: <i>Analgesic nitrous oxide for alcohol withdrawal is better than placebo</i> , Intern. J. Neuroscience, 1989, vol. 49, pp. 71-74
C9	Gillman et al.: <i>Analgesic Nitrous Oxide: Adjunct to Clonidine for Opioid Withdrawal</i> , American Journal of Psychiatry, June 1985, vol. 142, pp. 784-785
C10	Gillman et al.: <i>Analgesic nitrous oxide for alcohol withdrawal: a critical appraisal after 10 years' use</i> , Postgrad. Med. J. Clinical Toxicology, 1990, vol. 66, pp. 543-546

Examiner	Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.